Coherus Oncology
CHRS
75 hedge funds and large institutions have $387M invested in Coherus Oncology in 2016 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 28 increasing their positions, 17 reducing their positions, and 18 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 17
57% more capital inflows, than outflows
Capital inflows: $55.5M | Capital outflows: $35.4M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
3.82% more ownership
Funds ownership: 42.76% → 46.59% (+3.8%)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
3% less funds holding
Funds holding: 77 → 75 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.7M |
| 2 |
JP Morgan Chase
New York
|
+$7.64M |
| 3 |
Axa
Paris,
France
|
+$7.35M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.25M |
| 5 |
Bridger Management
New York
|
+$5.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$8.43M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$6.52M |
| 3 |
Highland Capital Management (Texas)
Dallas,
Texas
|
-$5.14M |
| 4 |
PFM Health Sciences
San Francisco,
California
|
-$3.96M |
| 5 |
Soros Fund Management
New York
|
-$2.93M |
CHRS Hedge Fund Activity: Q1 2016 in Review
75 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2016, worth a combined $387M — up 0.8% from $384M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CHRS and 17 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 28 added.
The largest buyer was Fidelity Investments, adding an estimated $12.7M. The largest seller was Jennison Associates, exiting entirely with an estimated $8.43M sold.
- 75 institutional investors held Coherus Oncology (CHRS) as of Q1 2016, down from 77 in Q4 2015.
- Funds reported $387M of Coherus Oncology stock for Q1 2016, up 0.8% quarter-over-quarter.
- 17 funds opened new Coherus Oncology positions in Q1 2016 and 18 closed out, a net change of -1 holder.
- The largest Coherus Oncology buyer in Q1 2016 was Fidelity Investments, an estimated $12.7M added.
- The largest Coherus Oncology seller in Q1 2016 was Jennison Associates, an estimated $8.43M sold.
Based on aggregated 13F filings for Q1 2016.